Form 4: Athira Pharma CFO Andrew Gengos Reports Stock Transactions Following RSU Vesting

Andrew Gengos, CFO of Athira Pharma, reports acquisition and disposal of company stock related to RSU vesting and ESPP purchase.

Summary

• Andrew Gengos, CFO and Chief Business Officer of Athira Pharma, filed a Form 4 detailing changes in beneficial ownership.
• On May 20, 2024, Gengos acquired 10,000 shares of common stock through the Employee Stock Purchase Plan (ESPP) at a price of $1.34 per share.
• On September 3, 2024, 5,000 restricted stock units (RSUs) vested following the completion of the public readout of topline results of Athira's LIFT-AD Phase 2/3 clinical trial.
• On September 5, 2024, Gengos sold 1,272 shares at an average price of $0.566 to cover tax obligations related to the RSU vesting, with prices ranging from $0.5505 to $0.5751.
• Following these transactions, Gengos beneficially owns 97,532 shares of Athira Pharma common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document primarily reports routine transactions. The RSU vesting is a positive milestone, but the stock sale is a neutral event.

Positives

• The vesting of RSUs indicates the achievement of a milestone related to the LIFT-AD Phase 2/3 clinical trial readout.

Negatives

• The sale of shares to cover tax obligations could be perceived negatively, although it's a standard practice.

Risks

• The stock sales to cover tax obligations could exert downward pressure on the stock price.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the remaining RSUs.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. The vesting of RSUs is tied to the achievement of clinical trial milestones, which are critical for biotech companies like Athira Pharma.

Comparison to Industry Standards

• RSU grants and ESPPs are common compensation tools in the biotech industry to align management interests with shareholder value.
• The 'sell to cover' practice for tax obligations is a standard procedure among publicly traded companies.
• Comparable companies such as Biogen, Ionis Pharmaceuticals, and Sage Therapeutics also utilize similar equity compensation plans.

Stakeholder Impact

• Shareholders may be interested in the insider transactions, particularly in relation to the clinical trial milestones.
• Employees participating in the ESPP are directly impacted by the share price and purchase terms.

Key Dates